Status:
ENROLLING_BY_INVITATION
Role of Anti-TREK-1 Autoantibodies in SCVF
Lead Sponsor:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Conditions:
Short-coupled Ventricular Fibrillation
Idiopathic Ventricular Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial pro...
Detailed Description
Please refer to the uploaded study protocol
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Diagnosis of SCVF as per current criteria
- Willingness to provide written informed consent
Exclusion
- \- SCVF patients \< age 18
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06943365
Start Date
May 1 2025
End Date
December 31 2028
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut universitaire de cardiologie et pneumologie de Québec
Québec, Quebec, Canada, G1V4G5